within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BD09_LansoprazoleClarithromycinAndTinidazole;

model LansoprazoleClarithromycinAndTinidazole
  extends Pharmacolibrary.Drugs.ATC.A.A02BD09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A02BD09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This drug combination includes lansoprazole (a proton pump inhibitor), clarithromycin (a macrolide antibiotic), and tinidazole (a nitroimidazole antimicrobial). It is used primarily in the treatment of Helicobacter pylori infection associated with peptic ulcer disease. Lansoprazole suppresses gastric acid secretion, while clarithromycin and tinidazole act as antibiotics targeting the bacteria. The combination is approved in some countries as a therapy for H. pylori eradication.</p><h4>Pharmacokinetics</h4><p>No direct publication with full pharmacokinetic parameters for the fixed-dose combination of lansoprazole, clarithromycin, and tinidazole is available. The following parameters are estimated based on available pharmacokinetic data of each individual component in healthy adults (both sexes, mean age ~30 years) after oral administration.</p><h4>References</h4><ol><li><p>Fitton, A, &amp; Wiseman, L (1996). Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. <i>Drugs</i> 51(3) 460â€“482. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199651030-00012&quot;>10.2165/00003495-199651030-00012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8882382/&quot;>https://pubmed.ncbi.nlm.nih.gov/8882382</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LansoprazoleClarithromycinAndTinidazole;
